SEATTLE, Sept. 13, 2013 /PRNewswire/ -- Adaptive Biotechnologies announced today that it received a $2.53 million Phase II Small Business Innovation Research award from the National Heart, Lung, and Blood Institute, a division of the NIH, to commercialize a test to measure the ability of a cancer patient's adaptive immune system to fight infection after a cord blood transplant. The phase II study follows promising phase I results presented at ASCO 2012 showing a statistical correlation between low diversity of infection-fighting immune cells (T-cells) and high likelihood of death from complications, including infection, during the first year after transplant.
It is widely recognized that the ability for a cord blood transplant recipient to reconstitute a healthy immune system is critical for overall survival. However, the existing standard of care only measures absolute T-cell counts, which did not show a correlation to the risk of infection in the phase I study.
"We are delighted to be the recipients of this important grant which aims to provide clinicians with a test to reliably identify patients who are not reconstituting a healthy, diverse immune system after transplant," said Chad Robins, CEO and Founder of Adaptive Biotechnologies.
"Identifying patients at risk for infection early after transplant is something that we strive to do in the clinic, but the current standard of using total T-cell counts seems to be suboptimal," said Dr. Colleen Delany, Cord Blood Transplant Program Director at The Fred Hutchinson Cancer Center. "We are pleased to be leading this effort to identify a better way to measure immunity and ultimately increase overall survival for our transplant patients."
|SOURCE Adaptive Biotechnologies Corporation|
Copyright©2012 PR Newswire.
All rights reserved